Daré Bioscience Q1 cash $3.6M, secures $22M royalty financing; Ovaprene Phase 3 ongoing

Dare Bioscience, Inc.

2024-Q1 EPS reported -$0.07 revenue$9,302

Cash & equivalents $3.6M at March 31, 2024; subsequent $22M non-dilutive royalty financing from XOMA and $1M grant installment.
R&D expenses $3.3M in Q1 2024, down 34% YoY from $5.0M; G&A $2.7M vs $3.3M.
Ovaprene Phase 3 contraceptive study recruiting at 18 US sites; central ad campaign launched March 2024.
Sildenafil Cream end-of-Phase 2 meeting with FDA completed; additional feedback expected 2Q2024 for Phase 3 design.
XACIATO commercialized by Organon since Q4 2023; first FDA-approved product from Daré portfolio.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dare Bioscience, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024, a copy of which is furnished as Exhibit 99.1 to this report.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-019087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.